Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators
Background. Emerging evidence suggests that nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery diseases and arrhythmias. The FibroScan (Echosens, France), a widely available, noninvasive device, is able to detect liver fibrosis and steatosis within this patient population. H...
Saved in:
Main Authors: | Yin Chan, Stephanie Pranke, Farid Rashidi, Shravan Nosib, Lawrence Worobetz |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Canadian Journal of Gastroenterology and Hepatology |
Online Access: | http://dx.doi.org/10.1155/2017/7298032 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Capsule Endoscopy in Patients with Cardiac Pacemakers and Implantable Cardioverter Defibrillators: (Re)evaluation of the Current State in Germany, Austria, and Switzerland 2010
by: Dirk Bandorski, et al.
Published: (2012-01-01) -
Chronic Kidney Disease and Mortality in Implantable Cardioverter-Defibrillator Recipients
by: Aamir Cheema, et al.
Published: (2010-01-01) -
Right Atrial Perforation Secondary to Implantable Cardioverter Defibrillator Insertion
by: Nam T Tran, et al.
Published: (2001-01-01) -
Risk factors for non-benefit of implantable cardioverter defibrillator therapy
by: Fabienne Kreimer, et al.
Published: (2025-01-01) -
The feasibility of using liver function indices and FibroScan in combination to predict the occurrence of anti-tuberculosis drug-induced liver injury in Patients with liver disease
by: Shaoqiang Wu, et al.
Published: (2025-01-01)